Hua Gong, M.D., Ph.D.

Sr. Director, Head of Genomics Biomarker Department at Navigate
BioPharma, a Novartis subsidiary.

Topic

Enabling oncology drug approval by successful development of
companion diagnostics

Dr. Gong designs “fit-for-purpose” biomarker assays to enable drug development and FDA approval.

Free Registration

Registration is free but required (max 70 registrants). Parking is free. Light food/snacks are provided. 

Speakers

Hua Gong, M.D., Ph.D. serves as Sr. Director, Head of Genomics
Biomarker Department at Navigate BioPharma, a Novartis
subsidiary. Her team has successfully enabled FDA approvals of
seven oncology drugs since 2013. Dr. Gong has more than 18 years
of experience in the development of drugs and diagnostics.
Previously, she was Executive Director of IVD & CDx at Premier
Research Group. At Prometheus Therapeutics & Diagnostics, she was
Associate Director, Medical Diagnostics, led development of
biomarker assays for pharmaceutical companies. Additionally, she
worked at Pfizer for 10 years in a variety of positions of increasing
responsibility. In her last position at Pfizer, Dr. Gong managed a
multi-disciplinary team including in-vitro/vivo biology, PDM, drug
safety and biomarker research groups. She was a key contributor for
an antibody drug that entered clinical development. Dr. Gong
received her medical training from An Hui Medical University, MS
degree from Sun Yat-Sen University and her Ph.D. degree in cancer
biology at Wayne State University.